Targeted drug tested to shrink tumors before lung cancer surgery
NCT ID NCT07274761
Summary
This study is testing whether a targeted drug called sunvozertinib can shrink tumors in people with a specific type of lung cancer before they have surgery. It is for adults with stage II-IIIB non-small cell lung cancer that has a particular genetic change called an EGFR exon 20 insertion. The main goal is to see how well the drug works and how safe it is when given for a few weeks prior to an operation to remove the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.